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Abstract
Temozolomide is used widely to treat malignant glioma but the overall response to this agent is 
generally poor. Resistance to DNA damaging drugs such as temozolomide has been related to the 
induction of anti-apoptotic proteins. Specifically, the transcription factor NF-κB has been 
suggested to participate in promoting the survival of cells exposed to chemotherapy. To identify 
factors that modulate cytotoxicity in the setting of DNA damage, we used an unbiased strategy to 
examine the NF-κB-dependent expression profile induced by temozolomide. By this route, we 
defined the decoy receptor DcR1 as a temozolomide response gene induced by a mechanism 
relying upon p50/NF-κB1. A conserved NF-κB binding sequence (κB-site) was identified in the 
proximal promoter and demonstrated to be required for DcR1 induction by temozolomide. Loss-
of-function and gain-of-function studies reveal that the atypical IκB protein, Bcl3, is also required 
for induction of DcR1 by temozolomide. Mechanistically, DcR1 attenuates temozolomide efficacy 
by blunting activation of the Fas receptor pathway in p53+/+ glioma cells. Intracranial xenograft 
studies show that DcR1 depletion in glioma cells enhances the efficacy of temozolomide. Taken 
together, our results show how DcR1 upregulation mediates temozolomide resistance, and provide 
a rationale for DcR1 targeting as a strategy to sensitize gliomas to this widely used chemotherapy.
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Introduction
Over the past decade, the oral alkylating agent temozolomide has become the standard 
chemotherapeutic for the management of malignant glioma. Specifically, the addition of 
temozolomide to ionizing radiation improves overall patient survival by approximately two 
months (1). Despite the clinical success of temozolomide, it is clear that many patients 
respond poorly to this agent at least in part due to the intrinsic resistance of tumor cells to 
damage-induced cell death. Temozolomide causes cytotoxicity by forming O6-
methylguanine (O6-MeG) adducts that mismatch with deoxythymidine residues and induce 
apoptosis following processing by the mismatch repair (MMR) system (2). While the repair 
protein O6-methylguanine DNA methyltransferase (MGMT) plays a prominent role in 
resistance to temozolomide (3,4), downstream factors that regulate induction of apoptosis 
are also important in the overall response.
Nuclear factor-κB (NF-κB) is a pivotal factor in the cytotoxic response to DNA damage (5). 
Although DNA double-strand breaks (DSBs) activate NF-κB by a well elucidated nuclear to 
cytoplasmic pathway (6), temozolomide and other replication stress-inducing agents 
modulate NF-κB signaling in a more complex, promoter-specific manner (7-9). The NF-κB 
family of proteins is comprised of five subunits: p50 (NF-κB1, p105), p52 (NF-κB2, p100), 
p65 (relA), relB, and crel that appear in their mature form as dimers (10). In general, NF-κB 
dimers are retained in the cytoplasm through interaction with the inhibitor-kB (IkB) proteins 
and, following translocation to the nucleus, mediate their effect by binding to specific 
consensus elements (κB-sites) in the promoter regions of genes. While all NF-κB subunits 
contain a conserved N-terminal rel homology domain (RHD), only p65, relB and crel have a 
C-terminal transactivation domain (TAD). p50 is a ubiquitously expressed NF-κB subunit 
that is targeted by the temozolomide-induced DNA damage response (8). Despite the lack of 
a TAD, p50 can induce NF-κB-dependent gene expression by associating with other rel 
subunits or co-regulator proteins. Bcl3 is one such NF-κB co-regulator that was originally 
identified at the t(14;19) chromosomal translocation in chronic lymphocytic leukemia 
patients (11,12). Bcl3 was subsequently found to be an atypical IkB protein that modulates 
NF-κB transcriptional activity in conjunction with p50- or p52-containing dimers (13). In 
this capacity, Bcl3 has been reported to induce the expression of anti-apoptotic factors such 
as Bcl2 or Hdm2 (14,15).
Apoptosis in response to temozolomide is reported to involve both the intrinsic, or 
mitochondrial, pathway and the extrinsic, or receptor-induced, response (16,17). The 
extrinsic pathway is initiated by receptor-ligand binding resulting in caspase-mediated cell 
death (18). TNF receptor superfamily members such as Fas receptor (Fas, CD95, Apo-1) 
and TNF-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1, DR4) or TRAIL-R2 
(DR5) mediate killing via the extrinsic response. In addition to these death receptors, two 
decoy receptors, DcR1 (TRAIL-R3, TRID, TNFRSF10C) and DcR2 (TRAIL-R4, 
TRUNDD), have been described. Decoy receptors do not induce cell death as they lack 
critical components that are necessary for apoptosis signaling (19). DcR1, a model decoy 
receptor, is found preferentially in untransformed cells (20) and attenuates apoptosis by 
competing with DR4 and DR5 or by forming an inactive heteromer with other death 
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receptors (21). DcR1, like other TRAIL receptors, is a p53 target gene with an intronic p53-
binding site (BS) that is induced by DNA damaging agents (22).
In the current study, using an unbiased genome-wide expression analysis, we identify DcR1 
as a factor significantly induced by temozolomide in a p50-dependent fashion. Mechanistic 
studies demonstrate that DcR1 is co-regulated by p50 and Bcl3 via a novel κB-site, and in 
vitro and animal studies demonstrate that depletion of DcR1 sensitizes gliomas to 
cytotoxicity by temozolomide. Together, these findings support the observation that 
temozolomide induces apoptosis via the death receptor pathway and suggest that targeting 
DcR1 is a strategy that can potentially enhance the anti-glioma effect of temozolomide 
clinically.
Materials and Methods
Cell lines, reagents and plasmids
Human U87, A172, T98 and U251 glioblastoma cells were purchased from American Type 
Culture Collection and authenticated by routine morphological and growth analysis and also 
by western blotting. Cells were cultured as previously described (8). U87 glioma cells 
expressing sh-p105 or sh-control were also previously described (8). pCMV-p50 was 
previously described (8), and used for experiments in Figure 4. HA-p50 was cloned from the 
template, p50 cFlag pcDNA3 (Addgene plasmid 20018), obtained from Dr. Stephen Smale, 
following excision of the Flag and insertion of an HA tag. The Bcl3 expression construct, 
Bcl3-pFlag-CMV2, was a kind gift from Dr. Albert Baldwin (University of North Carolina).
RNA interference and stable transfectants
The following siRNA constructs were obtained from Dharmacon: siGENOME Human Bcl3, 
si-p53 (M-3329-03), si-DcR1 (sc-40235) and si-scrambled control (D-001210-03-05). Also, 
si-p50 (sense: GUCACUCUAACGUAUGCAAUU) and si-control (sense: 
CCUACGCCACCAAUUUCGUUU) were obtained from Santa Cruz. All siRNA constructs 
were transfected using Oligofectamine (Invitrogen).
To make cells stably expressing sh-DcR1, PAGE-purified oligos (sense: 
GATCCGCTGAAGAGACAATGAACATTCAAGAGATGTTCATTGTCTCTTCAGCTT
TTTTACGCGTG and antisense: 
ATTCACGCGTAAAAAAGCTGAAGAGACAATGAACATCTCTTGAATGTTCATTGT
CTCTTCAGCG) or scrambled control, were obtained from IDT and annealed. Oligos were 
ligated into the BamHI and EcoRI sites of the retrovirus: pSIREN-RetroQ-DsRed 
(Clontech). For retroviral production, sh-control and sh-DcR1 vectors were co-transfected 
with pCMV-VSV-G into Plat-GP cells using Xtreme gene according to manufacturer's 
protocol (Roche). After 48 hours, the supernatant was cleared using a 0.45 μm syringe and 
concentrated using Clontech Retro-X at 3.5 ml per 1 ml of viral supernatant. The virus was 
collected by centrifugation at 1500 g for 45 minutes. The pellet was resuspended in regular 
media with 20 μl polybrene and added to U87 cells. Cells were split after 48 hours and 
maintained in regular media. 80- 90 % infection efficiency was determined by expression of 
Ds-Red, and knockdown of DcR1 verified by mRNA and protein analysis.
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Immunoblot and electrophoretic mobility shift assay (EMSA)
Immunoblotting was performed using whole cell lysate as previously described (23). 
Primary antibodies used include: anti-Bcl3 (Santa Cruz, sc185), anti-p21 (Santa Cruz, 
sc397), anti-p50 (Santa Cruz, sc7178), anti-GAPDH (Santa Cruz, sc-137179), anti-p53 
(Santa Cruz, sc71818), anti-DcR1 (R & D Systems, 398600), anti-HA (Covance, 
MMS-101R). Alexa-Fluor 680 and Alexa-Fluor 800 fluorescent dye-conjugated secondary 
antibodies (Invitrogen) were used for visualization with Odyssey Infrared system (LICOR 
Biosciences). EMSA was performed as previously described (8) with competition using cold 
specific and non-specific probes and supershift with anti-p50. The κB probe sequence is 
shown in Figure 4.
Quantitative real-time polymerase chain reaction (qPCR) and quantitative chromatin 
immunoprecipitation (qChIP)
qPCR was performed following total mRNA isolation as described (8). DCR1 was 
normalized to GAPDH and relative DCR1 mRNA expression is shown as the average of 
three experiments performed in triplicate. Primers used for DCR1 are: sense, 
CACCAACGCTTCCAACAATGAACC and antisense, 
TCCGGAAGGTGCCTTCTTTACACT.
qChIP was also performed as described (8) following IP with anti-p50 or anti-Bcl3 
antibodies. Control IP was performed using anti-Histone H1 and anti-mouse IgG. qPCR was 
performed using promoter-specific primers for human DcR1 that span the region 
encompassing the putative κB-site (sense, CCTCGACCATGCAAAGGGT and antisense, 
ACAGAATGAAGGACACAGGGG) and the change in DNA enrichment for each IP 
condition determined relative to input DNA. To control for non-specific binding, the anti-
p50 or anti-Bcl3 data was subtracted from the anti-H1 results (anti-IgG showed no binding) 
as previously described (8). The PCR product was also run on a gel for a semi-quantitative 
analysis of the data.
Flow cytometric analysis of apoptosis and DcR1 expression
Analysis of apoptosis was performed as described (24) at 72 or 96 hours following 
treatment. For DcR1 surface expression, cells were treated with temozolomide and 
trypsinized, washed with blocking buffer (PBS + 1% BSA) and centrifuged at 1500 RPM. 
The cell pellet was divided into 2 groups and incubated with anti-DcR1 (Abcam), or anti-
IgG control. Pellets were incubated with Alexa-fluor-conjugated secondary antibody and 
analyzed on an LSRII Flow Cytometer (BD Biosciences). Samples were run in triplicate and 
data analyzed using FlowJo (TreeStar Inc.).
Luciferase reporter and luciferase assay
For construction of a DcR1 luciferase reporter, we amplified a segment of DNA containing 
the DCR1 proximal promoter and part of intron 1 using fresh human genomic DNA with the 
following primers: GATAGACACTTGACTGGGGGAC and GAAGAACTGGGTC. After 
cloning the 1.232 kbp segment into the pCR II Topo Vector (Invitrogen), the DCR1 
sequence was liberated using XhoI and HindIII and ligated into the pGl4.20 luciferase 
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vector. Site-directed mutagenesis, using the QuickChange Lightning II mutagenesis kit, was 
used to mutate the κB and p53 BSs to the sequences indicated in Figure 4.
For luciferase assay, cells were co-transfected with the indicated reporter and Renilla 
reniformis and relative luciferase calculated after treatment with temozolomide as described 
(23). All experiments were performed in triplicate.
DcR1 cDNA cloning and lentiviral infection
The coding region of TNFRSF10C (NM_003841) was amplified (sense: 
AGCAGGCTCCGAATTCGCCACCATGGCCCGGATCCCCAAGACCCTA and 
antisense: AAGCTGGGTCGAATTCTCAAGCGTAATCTGGAACATCGTATGGG 
TAAACAAACACAATCAGAAGCACAATTAG) using genomic DNA from HEK293T 
cells. An HA tag was added to the C-terminus for immunoblot detection. This cDNA was 
then inserted into the pLVX-Puro vector (Clontech) and lentivirus generated using the 
packaging system from Addgene (pMD2.G and psPAX). U87 cells were then infected with 
HA-DcR1 lentivirus and selected with puromycin for 5 days.
Clonogenic and trypan blue assays
Assays were performed essentially as described (8,24). FAS neutralizing antibody (FNAb) 
was obtained from Millipore (#05-338). For clonogenic assay with FNAb, U87 cells were 
transfected with DCR1, or control, siRNA and after 48 hours replated. Cells were then 
treated with 25 μM temozolomide and 1 μg/ml FNAb (or vehicle). FNAb was re-
administered once 16 hours later and colony number counted at 2 weeks. Data show the 
change in surviving fraction in temozolomide treated samples in the presence and absence of 
FNAb in cells expressing the different siRNAs. Experiment was performed in triplicate and 
repeated. Clonogenic assay was performed after treatment of U87 cells with 30 ng/ml FAS 
ligand in the presence and absence of FNAb.
Nanoparticle (NP) production and characterization
NPs were manufactured and characterized as previously described (25) by LNK 
Chemsolutions LLC, USA. SiRNA constructs were incorporated into NPs in a similar 
fashion to incorporation of other agents (25) and the product maintained in sterile 
conditions.
Animal studies
Six to seven-week old male nude mice (Harlan) were used in accordance with guidelines of 
the Institutional Animal Care and Use Committee of the University of Chicago. For 
intracranial studies, 5x105 U87 cells were injected into the right striatum as previously 
described (24) and the animals randomized into 6 groups (n = 6 per group). 10 μL of either 
PBS or nanoparticles (NP) carrying si-Control or si-DcR1 were injected intracranially on 
day 4 and 7 following tumor inoculation. Mice were also treated with intraperitoneal (i.p.) 
injection of vehicle or temozolomide on day 4 (5 mg/kg), 7 (5 mg/kg) and 10 (2.5 mg/kg) 
(total temozolomide dose: 12.5 mg/kg). Animals were followed until terminal, sacrificed 
and brains harvested for verification of tumor.
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For hindlimb studies, 7.5x106 U87 cells were injected into the right hind limb and animals 
randomized into 6 groups (n = 5 per group) when tumors reached an average of 120 mm3 
(day 0). Mice were treated with daily intratumoral (i.t.) injection of 50 μl NPs containing 
either si-control or si-DcR1 for 5 consecutive days, and/or i.p. temozolomide (total dose: 
12.5 mg/kg). Control animals were injected i.t. or i.p. with vehicle. Tumor volume was 
measured and documented every 2- 3 days.
Statistical Analyses
Results are expressed as mean ±SD and significance determined as P < 0.05 using a 2-tailed 
student’s t-test.
RESULTS
TMZ induces DcR1 protein expression
To identify NF-κB-dependent factors that modulate the response to temozolomide, we 
performed an unbiased genome-wide expression analysis in isogenic glioma cells following 
treatment with temozolomide. U87 cells stably expressing sh-p105 or sh-control, described 
previously (8), were treated with temozolomide or vehicle and mRNA expression analyzed 
using the affymetrix Human Genome U133 Plus 2.0 Array. The expression data will be 
described in detail in a separate publication (Voce, D et. al. manuscript in preparation). 
DCR1 (TNFRSF10C) was identified as one of a small set of genes significantly induced only 
in p50-proficient cells following treatment (Supplementary Figure S1A). Given the 
importance of DcR1 in attenuating death receptor-induced apoptosis, we examined this 
decoy receptor in the response to temozolomide. DcR1 is induced within 24 hours in U87 
cells (Figure 1A) and the induction occurs in a concentration-dependent manner (Figure 1B). 
As DcR1 is a cell surface receptor, the change in DcR1 expression was quantified using 
flow cytometry and, consistent with the immunoblot analysis, DcR1 surface expression is 
induced by temozolomide (Supplementary Figure S1B). In addition, temozolomide induces 
expression of DCR1 mRNA (Figure 1C). These results indicate that temozolomide up-
regulates DcR1 in glioma cells.
DcR1 is induced in a p50 and p53 co-dependent manner
To verify the p50 dependence of DcR1, U87 cells expressing sh-p105 or sh-control were 
used. Consistent with the array findings, loss of p105/p50 blocks induction of DcR1 at the 
mRNA (Figure 2A) and protein level (Figure 2B). Moreover, knockdown of p105 also 
attenuates DcR1 surface expression (Supplementary Figure S1C). Importantly, re-expression 
of p50 in sh-p105 cells enables DcR1 induction, confirming that it is p50, and not p105, that 
is necessary for temozolomide-induced expression of DcR1 (Figure 2C). Of note, re-
expression of p50 is possible because the sh-p105 targets the C-terminal of p105 (8). DcR1 
is also a p53 target gene (22), and temozolomide increases expression of p53, and its 
downstream target p21, with a time course consistent with activation of DcR1 
(Supplementary Figure S1D). Knockdown of p53 blocks the ability of temozolomide to 
induce DCR1 mRNA in U87 cells (Figure 2D). In addition, consistent with p53-dependence, 
temozolomide does not induce DcR1 in either T98 or U251 glioma cells, both of which are 
p53 mutant, even at a concentration of 250 μM (Figure 2E). These results indicate that DcR1 
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is induced by temozolomide in a p50-dependent manner and also verify the importance of 
p53 in regulating DNA damage-induced DcR1.
DcR1 contains a conserved kB-site that binds p50
As our data indicate that DcR1 is transcriptionally regulated by NF-κB, we therefore 
searched the promoter and first intron of DCR1 (NCBI Gene ID: 8794) for potential NF-κB 
consensus elements. Using the program, TFSEARCH (26), a 10-nucleotide sequence sharing 
86% homology with the canonical kB-site was identified in the DCR1 proximal promoter 
(Figure 3A). DCR1 has only been described in primates (NCBI search TNFRSF10C) and an 
identical nucleotide sequence is found in other primate species (Figure 3B). Gel shift assay 
(EMSA) shows that the putative kB-site binds NF-κB in vitro and supershift analysis 
demonstrates that p50 is present within the NF-κB band (Figure 3C). Also, temozolomide 
does not alter the binding of NF-κB to the kB-site (Figure 3C). To examine whether p50 
binds the DCR1 promoter in vivo, ChIP assay was performed. p50 is recruited to the region 
of the DCR1 promoter containing the kB-site, and consistent with the EMSA, temozolomide 
does not significantly change this (Figure 3D). A blot of the PCR product further verifies the 
enrichment of p50 in this region (Supplementary Figure S2A, right).
To examine the functional significance of this consensus site, we constructed a luciferase 
reporter bearing a 1.232 kbp region encompassing the proximal promoter, exon 1 and a 
segment of the first intron of DCR1 (Figure 4A). Given information from previous DcR1 
promoter/reporters (22,27), our reporter was constructed to contain the p53 BS shown to be 
important for DcR1 induction. Temozolomide induces expression from this reporter that 
peaks at 12 hours (Figure 4B). Mutation of the p53 BS or kB-site blocks basal and induced 
reporter activity (Figure 4C) demonstrating that the putative kB-site is necessary for activity 
of the reporter. We next examined whether this site is regulated by p50. Knockdown of 
p105/p50 blocks induction of activity from the wildtype (wt) reporter in response to 
temozolomide (Figure 4D). Moreover, when p50 is re-expressed in sh-p105 cells, a 
substantial increase in basal activity is seen that is further increased by temozolomide 
(Figure 4D, right). These results suggest that a kB-site in the DCR1 promoter binds p50 and 
is required for p50-mediated induction by temozolomide.
Induction of DcR1 by temozolomide requires Bcl3
Despite the p50/p53 co-dependence of DcR1, in A172 cells that are p53-wt (28) and have 
abundant p50, temozolomide only slightly induces expression of DcR1 (Figure 5A). To 
further study this observation, we looked at the cytogenetics of A172 cells and noted that 
these cells have a significant deletion near chromosome 19q13.2 (29), a region containing 
the locus of the NF-κB co-regulator, BCL3. As Bcl3 plays a prominent role in p50-
dependent gene activation (30), we investigated whether DcR1 requires Bcl3 for induction 
by temozolomide. First, it is evident that although A172 cells do express Bcl3, they have 
substantially less than some other glioma cell lines (Figure 5B). Also, in U87 cells ChIP 
assay confirms that Bcl3 is bound to the DCR1 promoter and its recruitment minimally 
altered by treatment (Supplementary Figure S2A). Knock-down of Bcl3 completely blocks 
the ability of temozolomide to induce DCR1 mRNA (Figure 5C) and protein expression 
(Figure 5D). Moreover, depletion of Bcl3 blocks the ability of temozolomide to induce 
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activation of the DCR1 promoter/intron 1 reporter (Figure 5E). To confirm the role of Bcl3, 
we obtained a Bcl3 cDNA construct (gift from Dr. Albert Baldwin). Over-expression of 
Bcl3 in A172 cells enables temozolomide to induce DcR1 expression (Figure 5F) an 
observation also noted in U87 cells (Supplementary Figure S2B). Together, these data 
indicate that temozolomide requires Bcl3 to induce DcR1 expression.
Induction of DcR1 blocks the cytotoxic effect of temozolomide
DcR1 attenuates apoptosis (21) suggesting that its induction by temozolomide acts to block 
killing. Depletion of DcR1 leads to a significant increase in apoptosis following 
temozolomide treatment as assessed by annexin V binding (P < 0.05, Figure 6A). As a 
specificity control, we also constructed U87 cell lines expressing shRNAs targeting DcR1 or 
a scrambled sequence. Three DcR1 shRNA constructs were used and cell lines screened for 
knockdown of DcR1 using qPCR (Supplementary Figure S2C). Cells expressing sh-DcR1-3 
were selected and depletion of DcR1 protein confirmed by immunoblot (Figure 6B, inset). 
Sh-RNA depletion of DcR1 augments induction of apoptosis by temozolomide (Figure 6B) 
supporting the siRNA data and confirming that the effect is not due to the specific siRNA 
used. In addition, as temozolomide induces cytotoxicity at late times following treatment, 
we examined cell viability over time using trypan blue dye exclusion. Temozolomide 
increases the percentage of non-viable cells over time and knock-down of DcR1 augments 
this effect beginning 72 hours after treatment (Supplementary Figure S2D). As DcR1 is not 
induced by temozolomide in U251 cells, we also examined cytotoxicity in these cells. 
Knockdown of DcR1 does not affect induction of apoptosis by temozolomide in U251 cells 
(Supplementary Figure S3A).
We next examined clonal survival. Depletion of DcR1 augments the decrease in survival 
induced by temozolomide in U87 cells (Figure 6C) and to a lesser extent in A172 cells 
(Supplementary Figure S3B), likely due to the lower level of DcR1 induction in A172 cells 
compared to U87 cells. By contrast, in U251 cells no significant change in clonal survival is 
seen in response to temozolomide following DcR1 depletion compared to control 
(Supplementary Figure S3C). To further study the importance of DcR1, we cloned a cDNA 
of human HA-tagged DcR1 and constructed an HA-DcR1 lentiviral expression vector. U87 
cells were infected with this construct and stable expression of HA-DcR1 confirmed by 
immunoblot (Figure 6D). Over-expression of DcR1 significantly attenuates the decrease in 
clonal survival induced by temozolomide relative to vector control (Figure 6D). Taken 
together, over-expression and down-regulation studies indicate that DcR1 acts to attenuate 
the anti-glioma effect of temozolomide.
Given that DcR1 specifically blocks death receptor-induced cytotoxicity, we sought to 
examine whether DcR1 affects the temozolomide-induced death receptor response. It was 
previously noted that induction of apoptosis by temozolomide is attenuated by a FAS 
neutralizing antibody (FNAb) that blocks death receptor signaling (17). We used FNAb in 
temozolomide treated U87 cells that were initially transfected with siRNA targeting either 
DcR1 or a control sequence. While exposure to FNAb results in a 1.2-fold increase in clonal 
survival in temozolomide-treated cells expressing si-control, in cells depleted of DcR1 there 
is almost a 4-fold increase in survival in the presence of FNAb (Figure 6E). The observation 
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that blocking the death receptor response with FNAb has a more profound effect in the 
presence of DcR1 knockdown, suggests that DcR1 inhibits apoptosis induced by 
temozolomide specifically by affecting the death-receptor pathway. Importantly, we verified 
that in our hands FNAb does attenuate the decrease in survival induced by Fas ligand (FasL) 
(Supplementary Figure S4A). Moreover, although FNAb does not directly bind DcR1, both 
FNAb and DcR1 modulate apoptosis via the same receptor-mediated downstream signaling 
cascade (31). Consistent with DcR1 playing a role in the Fas response, while knockdown of 
DcR1 augments the effect of FasL (Supplementary Figure S4B), over-expression of DcR1 
completely blocks the effect of FasL (Supplementary Figure S4C). Of note, depletion of 
DcR1 has much less profound effect than DcR1 over-expression likely because of the low 
basal DcR1 level. In sum, these findings indicate that induction of DcR1 blocks death 
receptor-mediated cytotoxicity in response to temozolomide.
Knockdown of DcR1 enhances the effect of temozolomide in a glioma model
We next sought to examine DcR1 depletion in an animal glioma model. As there are no 
DcR1 inhibitors, blocking this factor requires a genetic approach. Stable sh-DcR1 cells do 
not form xenografts, therefore, we targeted DcR1 by encapsulating and delivering siRNA 
using a biodegradable nanoparticle (NP) vector previously described for the treatment of 
malignant glioma (25). NPs were fabricated to encapsulate either DcR1 siRNA (NP-si-
DcR1) or control siRNA (NP-si-cntl). Exposure of U87 cells to NP-si-DcR1 results in a 
decrease in DcR1 protein expression relative to vehicle or NP-si-cntl (Figure 7A). In 
addition, NP-si-DcR1 results in a significant decrease in clonal survival in combination with 
temozolomide relative to that with temozolomide and NP-si-cntl (Figure 7B). To examine 
efficacy in vivo, intracranial U87 glioma xenografts were established and NPs administered 
by direct intracranial injection. A significant increase in animal survival is seen in mice 
treated with combination temozolomide and NP-si-DcR1 compared to either agent alone or 
to the combination of temozolomide and NP-si-cntl (P < 0.01, log-rank: TMZ + NP-si-DcR1 
vs. TMZ + NP-si-cntl) (Figure 7C). A similar finding is also seen when hindlimb xenografts 
are treated with temozolomide and NPs (P < 0.01, TMZ + NP-si-DcR1 vs. NP-si-DcR1) 
(Supplementary Figures S4D). These findings indicate that in an established growing 
intracranial xenograft, depletion of DcR1 combines effectively with temozolomide to 
improve the anti-glioma effect.
Discussion
NF-κB plays a central role in regulating the cytotoxic response to DNA damage. To identify 
potential factors that modulate the cytotoxic effect of temozolomide, we examined the NF-
κB-dependent expression profile induced by this agent in glioma cells. DCR1, a decoy 
receptor that attenuates death receptor-induced apoptosis, was identified as an NF-κB/p50-
dependent gene significantly induced by treatment. Given that death receptor signaling is 
important for temozolomide-induced apoptosis (17), we examined the role of DcR1 in the 
response to temozolomide. Our findings demonstrate that DcR1 is induced by temozolomide 
in a manner dependent not only on p50 and p53, but also on the proto-oncogene, Bcl3. 
Moreover, we show that DcR1 attenuates the cytotoxic effect of temozolomide. In support 
of the ability of DcR1 to attenuate the anti-glioma response, examination of the Repository 
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for Molecular Brain Neoplasia Data (REMBRANDT) database indicates that patients with 
up-regulated DCR1 expression do significantly worse than others (Supplementary Figure 
S5) (32).
Although it has previously been reported that DNA damage can induce DcR1 and that this 
response attenuates sensitivity to TRAIL (33), up-regulation of DcR1 has not previously 
been reported to directly block DNA damage-induced killing. In demonstrating that 
inhibition of DcR1 augments killing by temozolomide, our data support the hypothesis that 
temozolomide induces cytotoxicity, at least in part, via the death receptor pathway (17). This 
hypothesis is further suggested by the finding that FNAb has a greater inhibitory effect on 
the temozolomide-induced response (i.e. causes a greater increase in survival) when DcR1 is 
depleted than when DcR1 is present.
The NF-κB-dependence of DcR1 is supported by identification of a conserved κB-site 
within the proximal promoter of the DCR1 gene. p50 binds this κB-site in vitro and is also 
recruited to the promoter region containing this sequence in vivo. Moreover, this consensus 
element is necessary for activation of a DcR1 promoter/reporter by temozolomide. Together, 
these findings support a functional role for the κB-site in regulating DcR1 expression in 
response to temozolomide. It is notable that the putative DCR1 κB-site contains a conserved 
deoxythymidine (T) residue at the −1 position. Interestingly, we previously reported that 
phosphorylation of p50 by temozolomide results in inhibition of NF-κB binding to κB-sites 
with a −1C or G, while binding to κB-sites with a −1A or −1T is unaltered (9). Consistent 
with this observation, p50 binding to the DCR1 κB-site (5’-GGGATGCCCC-3’) is 
unchanged following temozolomide treatment. In addition, the NF-κB-dependence of DcR1 
is also consistent with a previous study that noted that this gene is induced by crel and 
blocked by IkBα, respectively (34). Although a specific κB-site has not previously been 
reported for DCR1, functional consensus sequences have been identified for both DR4 and 
DR5 (35,36), death receptors that are highly homologous to DCR1 (31).
DcR1 is induced in a p50-dependent manner; however this NF-κB subunit lacks a TAD and 
requires either a rel subunit or additional factor to induce NF-κB-dependent gene 
expression. The atypical IκB protein, Bcl3, is an important NF-κB co-regulator that contains 
two TADs and has been shown to induce NF-κB-dependent gene expression in conjunction 
with DNA bound p50 (30). We demonstrate that Bcl3 is necessary for efficient DcR1 
expression in response to temozolomide. In support of this hypothesis, while loss of Bcl3 in 
U87 cells blocks the ability of temozolomide to induce DcR1, Bcl3 over-expression has the 
opposite affect, enhancing DcR1 induction. In addition, the findings that Bcl3 binds the 
DCR1 promoter in vivo and that Bcl3 depletion blocks temozolomide-induced expression 
from the DCR1 promoter/reporter support the hypothesis that this co-regulator directly 
modulates the expression of DcR1. From a mechanistic perspective, given the minimal 
change in p50 and Bcl3 recruitment to the DCR1 promoter following treatment (Figure 3D 
and Supplementary Figure S2A), it is likely that temozolomide promotes DcR1 expression 
by inducing NF-κB post-translational modifications and/or by inducing recruitment of 
additional p50- or Bcl3-dependent co-factors (37).
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DcR1, like its counterpart DcR2, was initially identified as a receptor preferentially 
expressed in normal tissues relative to cancer cells (20,38). However, it is evident that even 
in cancer cells DcR1 expression is inducible and attenuates DNA damage-induced 
cytotoxicity. Similarly, DcR2 is also induced by chemotherapeutics in malignant cells (39). 
These observations raise the possibility that targeting decoy receptors is a strategy that can 
potentially enhance the therapeutic effect of DNA damaging agents. Consistent with this 
hypothesis, we demonstrate that depletion of DcR1 enhances the cytotoxic effect of 
temozolomide. Moreover, by targeting DcR1 in an animal glioma model, we show that 
blocking expression of this receptor enhances the overall anti-glioma effect. Importantly, the 
in vivo effect of blocking DcR1 is demonstrated against a growing intracranial tumor whose 
cells were not previously manipulated to deplete DcR1, this finding highlights the potential 
of DcR1 as a viable clinical chemo-sensitizing target.
Despite the efficacy of RNA interference for targeted depletion of proteins, in vivo knock-
down of genes is hampered by various factors that include among other things, the 
protection of the siRNA and efficient delivery to the target tissue (40). To improve these 
aspects, we encapsulated the DcR1 siRNA in a biocompatible NP vector that directly 
delivers its payload to the cytoplasm (25). In addition, NPs were injected directly into the 
brain to concentrate delivery to the tumor cells. While siRNA-mediated DcR1 depletion is 
good for proof-of-principle studies in an animal model, ultimately, delivery of a 
pharmacological inhibitor may be a more effective strategy for clinical use.
Inhibition of cellular resistance pathways is an effective strategy to enhance the therapeutic 
effect of cytotoxic agents. Although blocking NF-κB can improve the anti-tumor effect of 
certain chemotherapeutics (41), this transcription factor has a variable role in cytotoxic 
signaling and is often required for cell death (8,42). Nevertheless, NF-κB promotes 
expression of many anti-apoptotic factors, suggesting that selective targeting of downstream 
NF-κB-dependent genes is a strategy that can be used to rationally enhance cytotoxicity. 
While temozolomide induces cell death primarily via the intrinsic apoptotic response in p53 
mutant gliomas, in p53 wt tumors the exogenous pathway predominates (17). DcR1 
represents an anti-apoptotic factor robustly induced by temozolomide that attenuates killing 
in p53 wt tumors. Given that virtually every patient diagnosed with malignant glioma is 
treated with temozolomide, targeting factors such as DcR1 can potentially make a 
significant impact on patient management specifically in tumors that are wt for p53.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Temozolomide induces DcR1 expression. A, immunoblot with anti-DcR1, or anti-GAPDH, 
antibody in U87 glioma cells at the indicated time following treatment with 100 μM 
temozolomide (TMZ). B, immunoblot with anti-DcR1 48 hours following treatment with 
TMZ. C, qPCR analysis of DCR1 mRNA expression in U87 cells 16 hours following 
treatment with indicated concentration of TMZ. Data show mean DCR1 transcript 
expression relative to GAPDH ± SD of triplicate samples from 3 separate biological 
experiments. *, P < 0.05.
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Figure 2. 
DcR1 is induced by temozolomide in a p50 and p53 co-dependent manner. A, qPCR 
analysis of DCR1 mRNA expression relative to GAPDH, ±SD from triplicate samples from 
3 experiments using U87 cells stably expressing sh-control (cntl) or sh-p105, 16 hours after 
treatment with vehicle or 100 μM temozolomide (TMZ). B, immunoblot with anti-DcR1 or 
anti-GAPDH in cells from (A), 48 hours following treatment with vehicle or TMZ. C, 
immunoblot with the indicated antibody in U87-sh-p105 cells transfected with HA-p50 or 
empty vector (EV) following treatment with vehicle or 250 μM TMZ (24 hours). D, qPCR 
analysis of DCR1 mRNA expression in U87 cells transfected with si-RNA following 
treatment with vehicle or 100 μM TMZ (16 hours). E, immunoblot with anti-DcR1 
following treatment of the indicated glioma cell lines with TMZ for 48 hours. *, P < 0.05.
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Figure 3. 
DCR1 contains a conserved kB-site that binds p50. A, schematic representation of DCR1 
showing the putative κB-site and p53 BS. B, conservation of DCR1 κB-site sequence in 
primates. C, EMSA with the DcR1 kB-site probe using nuclear extract from U87 cells 
treated with vehicle or 100 μM temozolomide (TMZ) (16 hours). Competition with specific 
and non-specific competitors (SC and NS), respectively. Supershift (SS) was performed 
using anti-p50. Oct1 EMSA (right) demonstrates equal lysate loading. D, qChIP using 
DCR1 promoter-specific primers spanning the putative kB-site. Data show chromatin 
enrichment of p50 relative to input after controlling for non-specific binding using anti-
histone H1 (positive control) and anti-IgG, normalized to vehicle, ± SD of 3 triplicate 
samples, repeated with similar results
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Figure 4. 
The kB-site and p50 are required for activation of a DCR1 promoter/intron 1 reporter by 
temozolomide. A, schematic representation of the 1.232 kbp luciferase reporter. B, 
luciferase expression relative to renilla in U87 cells using the wt-reporter following 
treatment with 100 μM temozolomide (TMZ) for the indicated time. C, relative luciferase 
activity from the indicated reporter following treatment of U87 cells with vehicle or 100 μM 
TMZ (12 hours). D, relative luciferase in sh-p105 and sh-control cells (left), and in sh-p105 
cells transfected with empty vector (EV) or p50 (right) following treatment as in (C). Inset: 
immunoblot with anti-p50 antibody. Luciferase data represent mean ±SD of triplicate 
samples. *, P < 0.01.
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Figure 5. 
Bcl3 is required for induction of DcR1 by temozolomide. A, immunoblot with anti-DcR1 in 
U87 and A172 cells following treatment with temozolomide (TMZ). B, immunoblot with 
anti-Bcl3 antibody using the indicated glioma cells (40 μg protein). Lower blot: U87 and 
A172 cells using 80 μg protein. C, qPCR analysis of mean DCR1 mRNA expression relative 
to GAPDH, ±SD of triplicate samples in U87 cells transfected with siRNA following 
treatment (TMZ: 100 μM). Inset: immunoblot with anti-Bcl3. D, immunoblot with anti-
DcR1 in cells transfected and treated as in (C). E, relative luciferase expression following 
treatment with vehicle or 100 μM TMZ (16 hours) using the wt reporter in cells transfected 
as in (C), mean ±SD of triplicate samples shown. F, immunoblot at 48 hours with anti-DcR1 
(upper) or anti-Bcl3 (lower) antibody in A172 cells transfected with empty vector (EV) or 
Bcl3 and treated as shown. *, P < 0.05.
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Figure 6. 
Depletion of DcR1 sensitizes cells to temozolomide. A, annexin V binding in U87 cells 
treated as shown (TMZ: 100 μM, 72 hours) following transfection with the indicated siRNA. 
B, annexin V binding at 96 hours in U87 shRNA clones treated as shown (TMZ: 100 μM). 
Inset: immunoblot with anti-DcR1. C, clonogenic assay in U87 cells transfected with the 
indicated siRNA and treated with temozolomide (TMZ). D, clonogenic assay in U87 clones 
expressing HA-DcR1 or empty vector (EV) following treatment with TMZ. Inset: 
immunoblot with anti-DcR1 or anti-HA. E, clonogenic assay in U87 cells transfected with 
the indicated siRNA, treated with 25 μM TMZ and 1 μg/ml FNAb (twice) or vehicle. Data 
show survival following TMZ treatment in samples treated with FNAb relative to those 
without FNAb in each siRNA group. All data represent mean ±SD of triplicate samples, 
repeated with similar findings. *, P < 0.05. **, P < 0.01.
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Figure 7. 
Knockdown of DcR1 enhances the anti-glioma effect of temozolomide. A, immunoblot with 
anti-DcR1 antibody in U87 cells treated with vehicle or nanoparticles (NP) carrying the 
indicated siRNA. B, clonogenic assay in U87 cells treated with vehicle or the indicated NP 
and temozolomide (TMZ). *, P < 0.05. C, Kaplan-Meier survival curves of mice bearing 
intracranial gliomas (n= 6 mice per group) following treatment with TMZ (days 4, 7 and 10) 
at the concentrations indicated, and/or NPs carrying the indicated siRNA. P < 0.01, Log-
rank: TMZ + NP-si-DcR1 vs. NP-si-DcR1 or TMZ + NP-si-cntl.
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